Skip to content

Azenta

US · AZTA #2893 by market cap Listed 1970
44.80 -2.29 -4.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.36 Expensive vs history 78th percentile
5-year average 1.45 · #11 of 51 in Medical Instruments & Supplies
P/E ratio -12.34 In line with history 56th percentile
5-year average -33.00 · forward 176.50
P/S ratio 3.07 In line with history 35th percentile
5-year average 5.07 · forward 2.92 · #30 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Azenta (AZTA) 1.88B -12.11 1.34 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value47.24 Economic moatNone UncertaintyHigh

Trading 5.4% below Morningstar's fair value estimate.

Fair value

Azenta Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 3% discount to our quantitative fair value estimate of $47.24 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics strengthen our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 88.1%, which falls in the top 40% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.8%, for example, falls in the bottom 40% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Azenta discussion 0 comments

Add a comment